Starting November 2019, we are excited to present a new monthly feature – Paper of the Month.

This feature was initiated by the Council of Fellows to highlight interesting and relevant papers published by ESO members or with special relevance to Europe. Paper of the Month nominations will come from the recently formed working  group of the same name. Additionally all ESO members are invited to nominate appropriate papers for recognition as Paper of the Month. More details as well as an archive can be found on the Paper of the Month webpage.

Each paper will be presented in the second half of the month accompanied by a brief comment by a member of the group.

On behalf of the Paper of the Month group, we hope you enjoy the read!

Paper of the Month Group: Christine Roffe, Marie Louisa Zedde, Stefano Ricci, Augusto Zaninelli, Vladimir Nosal, Hughes Chabriat, Nishant Mishra, Anita Arsovska, Ana Fonseca, Diana Aguiar de Sousa, Mario Di Napoli, and Nicolas Martinez-Majander

November

This month’s paper is of particular interest as it addresses an area of clinical uncertainty which affects daily practice. Should we bridge with full dose heparin/low molecular weight heparin when faced with a patient in AF who has had a minor stroke? Altavilla et al’s large observational study suggests ‘no’. Both ischemic and haemorrhagic strokes were more frequent in the bridged group. However, the study is not randomized, and neither multivariate analysis nor propensity matching can fully exclude biases. However, while we are waiting for results of on-going clinical trials such as ELAN, these results should make us stop and think when considering bridging.

Anticoagulation After Stroke in Patients With Atrial Fibrillation To Bridge or Not With Low-Molecular-Weight Heparin?

Originally publishedhttps://doi.org/10.1161/STROKEAHA.118.022856 Stroke. 2019;50:2093–2100